Mesenchymal Stem Cell Therapy in Diabetic Kidney Disease-A Double-blind, Placebo-controlled, Randomized Clinical Trial

Diabetes cases increased from 108 million in 1980 to 422 million in 2014 worldwide. Its prevalence has risen more rapidly in low- and middle-income countries than in high-income countries. It has become the leading cause of blindness, kidney failure, heart attacks, stroke and amputation of lower limbs. Damage to kidneys due to high blood is a serious threat, over time they stop the filtration process blood, leading to Chronic Kidney Disease. Approximately 1 in 3 adults with diabetes has CKD, which leads to kidney failure in worst cases and the only options left for the patient are regular dialysis or kidney transplant. Both these options are usually scarce, unaffordable and unavailable in developing countries like Pakistan. In finding an easier and effective treatment option for CKD secondary to diabetes it was found that MSCs can stop tissue damage progression in CKD, this has been extensively investigated in preclinical studies till now. Bone marrow derived MSCs are multipotent, including hematopoietic stem cell, mesenchymal stromal cells and endothelial progenitor cell. MSCs have anti-inflammatory and antifibrotic properties and can suppress maturation, activation and proliferation of T, B and NK cells in vitro and down regulate immune response in vivo. Beneficial effects of MSCs are seen largely through immunomodulatory and paracrine mechanisms like production of growth factors and cytokines with immunosuppressive, anti-inflammatory, anti-apoptotic and proliferative effects. Cultured MSCs release large amounts of pro-angiogenic factor; vascular endothelial growth factor which facilitates glomerular and tubular recovery. MSC therapy in CKD-preclinical studies have shown that single dose of bone marrow-derived MSCs in rats decreased interstitial fibrosis, tubular atrophy, T-cell and macrophage infiltration, and the expression of inflammatory cytokines. This has been attributed to their paracrine immunomodulatory properties rather than long-term engraftment. MSCs also have the capacity to induce proliferation of renal glomerular and tubular cells and increase cellular survival. In preclinical studies injected MSCs secrete pro-angiogenic and trophic factors which enhance proliferation and decrease apoptosis of tubular cells. However, engraftment and trans-differentiation was not observed in the majority of the studies. Although there is a large gap between scientific knowledge and clinical translation for a safe and effective stem cell-based therapy, stem cells hold great promise for the treatment of CKD. We aim to study the efficacy of MSCs treatment in diabetic nephropathy CKD stage 2 and 3 due to type 2 Diabetes Mellitus. For this purpose, we have designed a randomized, double-blinded, placebo-controlled clinical trial to determine the efficacy of MSC therapy in chronic kidney disease.

Inclusion criteria

Male and female patients between 18 and 75 years of age having Type-2 Diabetes with CKD stage 2,3 and 4: (eGFR 15-90 mL/min/1.73 m2).

Exclusion criteria

Patients with a history of other comorbidities like previous myocardial infarction, pulmonary disease, pregnant females, unable to follow or return for evaluation.